Clinical Implication of Drug Resistance for H. pylori Management

Area of Science:

• Microbiology
• Infectious Diseases
• Clinical Pharmacology

Background:

• Increasing antimicrobial resistance in *Helicobacter pylori* (*H. pylori*) strains globally is reducing the effectiveness of standard eradication therapies.
• Current empiric treatment regimens, particularly those including clarithromycin or levofloxacin, are facing declining success rates due to widespread resistance.

Purpose of the Study:

• To review the mechanisms and global patterns of *H. pylori* antimicrobial resistance.
• To discuss the clinical utility and challenges of antimicrobial susceptibility testing (AST) for guiding *H. pylori* treatment.
• To explore the potential of susceptibility-based (tailored) therapy for improving eradication outcomes.

Main Methods:

• Comprehensive review of existing literature on *H. pylori* resistance mechanisms and global resistance patterns.
• Analysis of conventional culture-based and novel sequencing-based methods for AST in clinical settings.
• Evaluation of clinical trial data comparing tailored versus empiric treatment strategies.

Main Results:

• Antimicrobial resistance is a significant and growing global challenge for *H. pylori* eradication.
• Both traditional culture-based and newer molecular methods can assess susceptibility, though challenges remain in routine clinical implementation.
• While direct superiority of tailored therapy is not yet definitively proven in all trials, AST provides valuable data for treatment selection.

Conclusions:

• A shift from empiric to susceptibility-guided *H. pylori* treatment is necessary to combat rising resistance.
• Advancements in AST methods offer promising tools for personalized *H. pylori* management.
• Widespread adoption of AST is expected to enhance future *H. pylori* eradication success.